Sophiris Bio Stock Price, News & Analysis (NASDAQ:SPHS)

$2.29 0.01 (0.44 %)
(As of 01/16/2018 04:00 PM ET)
Previous Close$2.28
Today's Range$2.25 - $2.34
52-Week Range$1.80 - $3.24
Volume121,200 shs
Average Volume253,767 shs
Market Capitalization$68.95 million
P/E Ratio-17.62
Dividend YieldN/A
Beta2.03

About Sophiris Bio (NASDAQ:SPHS)

Sophiris Bio logoSophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.

Receive SPHS News and Ratings via Email

Sign-up to receive the latest news and ratings for SPHS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:SPHS
CUSIPN/A
Phone+1-858-7771760

Debt

Debt-to-Equity Ratio0.60%
Current Ratio13.37%
Quick Ratio13.37%

Price-To-Earnings

Trailing P/E Ratio-17.6153846153846
Forward P/E Ratio-8.81
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.48 per share
Price / Book4.77

Profitability

Trailing EPS($0.13)
Net Income$-11,160,000.00
Net MarginsN/A
Return on Equity-85.20%
Return on Assets-38.89%

Miscellaneous

Employees5
Outstanding Shares30,110,000

Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions

What is Sophiris Bio's stock symbol?

Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."

How were Sophiris Bio's earnings last quarter?

Sophiris Bio Inc (NASDAQ:SPHS) issued its earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.01. View Sophiris Bio's Earnings History.

When will Sophiris Bio make its next earnings announcement?

Sophiris Bio is scheduled to release their next quarterly earnings announcement on Monday, March, 26th 2018. View Earnings Estimates for Sophiris Bio.

Where is Sophiris Bio's stock going? Where will Sophiris Bio's stock price be in 2018?

4 analysts have issued 12 month price targets for Sophiris Bio's stock. Their forecasts range from $6.00 to $7.00. On average, they expect Sophiris Bio's share price to reach $6.25 in the next year. View Analyst Ratings for Sophiris Bio.

What are Wall Street analysts saying about Sophiris Bio stock?

Here are some recent quotes from research analysts about Sophiris Bio stock:

  • 1. Maxim Group analysts commented, "Sophiris announced that the last patient to be dosed with topsalysin (P2b study in men with localized prostate cancer -PC), should occur by month’s end." (10/2/2017)
  • 2. Rodman & Renshaw analysts commented, "Sophiris announced 2016 results yesterday, posting losses per share for the quarter and year of ($0.02) and ($0.49), respectively, compared to our estimates of ($0.10) and ($0.45) and consensus of ($0.11) and ($0.52). The company ended the year with $29.0M in cash, which management believes provides runway through the end of 2018. Complete localized prostate cancer Phase 2a proof-of-concept data in hand. Last week, Sophiris presented the detailed results from its small, 18-patient proof of concept Phase 2a in localized prostate cancer at the European Association of Urology. Recall, 11 patients had a response to PRX302, which included two complete ablations of target tumor tissue and nine partial tumor ablations. Six patients had tumor growth and one patient had no change in tumor volume. These data were achieved despite not having an optimized dose and delivery method. Adverse events were mild in severity and were associated with PRX302 and/or the injection technique. In summary, administration of PRX302 displayed clinical activity with the ability to ablate prostate tumor cells with minimal genitourinary side effects." (3/28/2017)

Who are some of Sophiris Bio's key competitors?

Who are Sophiris Bio's key executives?

Sophiris Bio's management team includes the folowing people:

  • Lars Ekman M.D., Ph.D., Executive Chairman of the Board
  • Randall E. Woods, President, Chief Executive Officer, Director
  • Peter T. Slover CPA, Chief Financial Officer
  • Allison J. Hulme Ph.D., Chief Operating Officer, Head - Research & Development
  • Iain R. Mant, Corporate Secretary
  • Joseph L. Turner Jr., Director (Age 61)
  • John Geltosky Ph.D., Independent Director
  • James Heppell, Independent Director
  • William R. Rohn, Independent Director (Age 69)

How do I buy Sophiris Bio stock?

Shares of Sophiris Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sophiris Bio's stock price today?

One share of Sophiris Bio stock can currently be purchased for approximately $2.29.

How big of a company is Sophiris Bio?

Sophiris Bio has a market capitalization of $68.95 million. The biopharmaceutical company earns $-11,160,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis. Sophiris Bio employs 5 workers across the globe.

How can I contact Sophiris Bio?

Sophiris Bio's mailing address is 1258 Prospect Street, LA JOLLA, CA 92037, United States. The biopharmaceutical company can be reached via phone at +1-858-7771760 or via email at [email protected]


MarketBeat Community Rating for Sophiris Bio (SPHS)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  53 (Vote Underperform)
Total Votes:  182
MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sophiris Bio (NASDAQ:SPHS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.25$6.25$6.60$6.60
Price Target Upside: 230.69% upside230.69% upside207.55% upside171.60% upside

Sophiris Bio (NASDAQ:SPHS) Consensus Price Target History

Price Target History for Sophiris Bio (NASDAQ:SPHS)

Sophiris Bio (NASDAQ:SPHS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2017Maxim GroupSet Price TargetBuy$6.00HighView Rating Details
11/10/2017HC WainwrightReiterated RatingBuy$6.00N/AView Rating Details
6/1/2017Rodman & RenshawReiterated RatingBuy$6.00HighView Rating Details
4/6/2017Piper Jaffray CompaniesReiterated RatingOverweight$7.00MediumView Rating Details
11/11/2016Roth CapitalReiterated RatingBuy$8.00N/AView Rating Details
6/10/2016Echelon Wealth PartnersReiterated RatingBuy$5.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Sophiris Bio (NASDAQ:SPHS) Earnings History and Estimates Chart

Earnings by Quarter for Sophiris Bio (NASDAQ:SPHS)

Sophiris Bio (NASDAQ SPHS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/26/2018($0.11)N/AView Earnings Details
11/9/2017Q3 2017($0.10)($0.11)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.09)($0.09)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.09)($0.09)ViewN/AView Earnings Details
3/27/2017Q4 2016($0.11)($0.02)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.09)($0.15)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.21)ViewN/AView Earnings Details
5/16/2016Q1($0.19)($0.13)ViewN/AView Earnings Details
3/23/2016Q4($0.15)ViewN/AView Earnings Details
11/16/2015Q3($0.22)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.22)ViewN/AView Earnings Details
5/13/2015($0.30)($0.26)ViewN/AView Earnings Details
3/10/2015($0.47)($0.31)ViewN/AView Earnings Details
11/13/2014($0.54)($0.49)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.47)($0.53)ViewN/AView Earnings Details
5/13/2014Q114($0.50)($0.52)ViewN/AView Earnings Details
3/13/2014Q4 2013($0.33)($0.37)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.43)($0.30)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Sophiris Bio (NASDAQ:SPHS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.26 EPS
Next Year EPS Consensus Estimate: $-0.47 EPS

Dividends

Dividend History for Sophiris Bio (NASDAQ:SPHS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Sophiris Bio (NASDAQ SPHS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 5.47%
Insider Trades by Quarter for Sophiris Bio (NASDAQ:SPHS)
Institutional Ownership by Quarter for Sophiris Bio (NASDAQ:SPHS)

Sophiris Bio (NASDAQ SPHS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2014Boxer Capital, LlcMajor ShareholderSell881,479$0.61$537,702.19View SEC Filing  
11/14/2014Randall E WoodsInsiderBuy3,000$2.43$7,290.00View SEC Filing  
9/19/2014Gerald T ProehlDirectorBuy10,000$3.16$31,600.00View SEC Filing  
7/10/2014Randall E WoodsInsiderBuy1,000$2.65$2,650.00View SEC Filing  
7/9/2014Randall E WoodsInsiderBuy1,000$2.66$2,660.00View SEC Filing  
6/6/2014James L HeppellDirectorSell19,231$2.59$49,808.29View SEC Filing  
8/22/2013Randall E WoodsCEOBuy2,500$4.50$11,250.00View SEC Filing  
8/20/2013Peter T SloverCFOBuy4,680$4.25$19,890.00View SEC Filing  
8/19/2013Randall E WoodsCEOBuy10,000$4.29$42,900.00View SEC Filing  
8/16/2013Boxer Capital, LlcMajor ShareholderBuy1,600,000$5.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sophiris Bio (NASDAQ SPHS) News Headlines

Source:
DateHeadline
Sophiris Bio to Participate in the 10th Annual Biotech Showcase ConferenceSophiris Bio to Participate in the 10th Annual Biotech Showcase Conference
finance.yahoo.com - December 27 at 9:12 AM
Reviewing Sophiris Bio (SPHS) & SciClone Pharmaceuticals (SCLN)Reviewing Sophiris Bio (SPHS) & SciClone Pharmaceuticals (SCLN)
www.americanbankingnews.com - December 22 at 5:54 PM
ValuEngine Upgrades Sophiris Bio (SPHS) to "Sell"ValuEngine Upgrades Sophiris Bio (SPHS) to "Sell"
www.americanbankingnews.com - December 16 at 3:36 PM
Sophiris Bio (SPHS) Reports Complete Enrollment in Phase 2b ... - StreetInsider.comSophiris Bio (SPHS) Reports Complete Enrollment in Phase 2b ... - StreetInsider.com
www.streetinsider.com - December 12 at 6:58 AM
Maxim Group Analysts Give Sophiris Bio (SPHS) a $6.00 Price TargetMaxim Group Analysts Give Sophiris Bio (SPHS) a $6.00 Price Target
www.americanbankingnews.com - December 11 at 5:08 PM
Sophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate CancerSophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate Cancer
finance.yahoo.com - December 11 at 3:20 PM
Sophiris Bio to Participate in the 29th Annual Piper Jaffray ... - PR Newswire (press release)Sophiris Bio to Participate in the 29th Annual Piper Jaffray ... - PR Newswire (press release)
www.prnewswire.com - November 28 at 11:00 AM
Sophiris Bio to Participate in the 29th Annual Piper Jaffray Healthcare ConferenceSophiris Bio to Participate in the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 27 at 4:12 PM
Is Sophiris Bio Inc’s (SPHS) Balance Sheet Strong Enough To Weather A Storm?Is Sophiris Bio Inc’s (SPHS) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 22 at 8:26 AM
Is Sophiris Bio Inc’s (SPHS) Balance Sheet Strong Enough To Weather A Storm?Is Sophiris Bio Inc’s (SPHS) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 22 at 8:26 AM
SPHS: First Dosing in Phase 2b Trial of Topsalysin in Prostate Cancer Almost Complete; Data in 1H18SPHS: First Dosing in Phase 2b Trial of Topsalysin in Prostate Cancer Almost Complete; Data in 1H18
finance.yahoo.com - November 20 at 4:39 PM
Contrasting Sophiris Bio (SPHS) & Its RivalsContrasting Sophiris Bio (SPHS) & Its Rivals
www.americanbankingnews.com - November 19 at 1:16 PM
Sophiris Bio (SPHS) versus Amicus Therapeutics (FOLD) Critical ComparisonSophiris Bio (SPHS) versus Amicus Therapeutics (FOLD) Critical Comparison
www.americanbankingnews.com - November 19 at 5:22 AM
Zacks: Analysts Anticipate Sophiris Bio, Inc. (SPHS) to Post -$0.11 Earnings Per ShareZacks: Analysts Anticipate Sophiris Bio, Inc. (SPHS) to Post -$0.11 Earnings Per Share
www.americanbankingnews.com - November 15 at 11:38 AM
Analyzing Sophiris Bio (SPHS) and The CompetitionAnalyzing Sophiris Bio (SPHS) and The Competition
www.americanbankingnews.com - November 14 at 5:31 PM
Sophiris Bios (SPHS) Buy Rating Reaffirmed at HC WainwrightSophiris Bio's (SPHS) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - November 12 at 12:58 AM
Sophiris Bio Reports Third Quarter Financial Results and Key Corporate HighlightsSophiris Bio Reports Third Quarter Financial Results and Key Corporate Highlights
finance.yahoo.com - November 9 at 7:02 PM
Sophiris Bio, Inc. (SPHS) Set to Announce Quarterly Earnings on TuesdaySophiris Bio, Inc. (SPHS) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:52 AM
 Brokerages Expect Sophiris Bio, Inc. (SPHS) to Post -$0.10 Earnings Per Share Brokerages Expect Sophiris Bio, Inc. (SPHS) to Post -$0.10 Earnings Per Share
www.americanbankingnews.com - October 25 at 11:30 PM
Sophiris Bio, Inc. (SPHS) Receives Consensus Recommendation of "Buy" from AnalystsSophiris Bio, Inc. (SPHS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 4 at 6:02 PM
Sophiris Bio Says Patient Enrollment is Nearly Complete in Phase 2b Study of Treatment for Prostrate CancerSophiris Bio Says Patient Enrollment is Nearly Complete in Phase 2b Study of Treatment for Prostrate Cancer
www.nasdaq.com - October 3 at 12:45 PM
Sophiris Bio Provides Enrollment Update on Topsalysin Phase 2b Study in Localized Prostate CancerSophiris Bio Provides Enrollment Update on Topsalysin Phase 2b Study in Localized Prostate Cancer
finance.yahoo.com - October 3 at 12:45 PM
Maxim Group Reiterates Buy Rating for Sophiris Bio, Inc. (SPHS)Maxim Group Reiterates Buy Rating for Sophiris Bio, Inc. (SPHS)
www.americanbankingnews.com - October 2 at 11:24 AM
Sophiris Bio (SPHS) Announces Enrollment Update on Topsalysin Phase 2b Study in Localized Prostate Cancer - StreetInsider.comSophiris Bio (SPHS) Announces Enrollment Update on Topsalysin Phase 2b Study in Localized Prostate Cancer - StreetInsider.com
www.streetinsider.com - October 2 at 9:20 AM
HC Wainwright Reaffirms "Buy" Rating for Sophiris Bio, Inc. (SPHS)HC Wainwright Reaffirms "Buy" Rating for Sophiris Bio, Inc. (SPHS)
www.americanbankingnews.com - September 15 at 4:52 PM
Sophiris Bio Secures up to $10 Million in Term Loans from Silicon Valley BankSophiris Bio Secures up to $10 Million in Term Loans from Silicon Valley Bank
finance.yahoo.com - September 14 at 10:28 AM
Sophiris Bio, Inc. (SPHS) Receives Consensus Rating of "Buy" from AnalystsSophiris Bio, Inc. (SPHS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 9 at 2:50 PM
Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - PR Newswire (press release)Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - PR Newswire (press release)
www.prnewswire.com - August 19 at 7:44 AM
Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment ConferenceSophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - August 18 at 7:27 AM
Sophiris Bio, Inc. (SPHS) Given Average Rating of "Buy" by BrokeragesSophiris Bio, Inc. (SPHS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 15 at 6:32 PM
HC Wainwright Reiterates "$6.00" Price Target for Sophiris Bio, Inc. (SPHS)HC Wainwright Reiterates "$6.00" Price Target for Sophiris Bio, Inc. (SPHS)
www.americanbankingnews.com - August 13 at 3:32 PM
Sophiris Bio Reports Second Quarter Financial Results and Key Corporate HighlightsSophiris Bio Reports Second Quarter Financial Results and Key Corporate Highlights
finance.yahoo.com - August 11 at 8:45 AM
 Brokerages Anticipate Sophiris Bio, Inc. (SPHS) to Post -$0.09 Earnings Per Share Brokerages Anticipate Sophiris Bio, Inc. (SPHS) to Post -$0.09 Earnings Per Share
www.americanbankingnews.com - July 25 at 9:03 AM
Contrasting Parnell Pharmaceuticals Holdings (PARN) and Sophiris Bio (SPHS)Contrasting Parnell Pharmaceuticals Holdings (PARN) and Sophiris Bio (SPHS)
www.americanbankingnews.com - July 23 at 7:25 AM
Sophiris Bio, Inc. (NASDAQ:SPHS) Given Consensus Rating of "Buy" by BrokeragesSophiris Bio, Inc. (NASDAQ:SPHS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 21 at 6:50 PM
Mylan N.V. (MYL) and Sophiris Bio (SPHS) Head-To-Head ReviewMylan N.V. (MYL) and Sophiris Bio (SPHS) Head-To-Head Review
www.americanbankingnews.com - July 16 at 6:20 PM
Comparing Sophiris Bio (SPHS) & Mylan N.V. (MYL)Comparing Sophiris Bio (SPHS) & Mylan N.V. (MYL)
www.americanbankingnews.com - July 11 at 8:26 PM
Financial Analysis: Parnell Pharmaceuticals Holdings (PARN) & Sophiris Bio (NASDAQ:SPHS)Financial Analysis: Parnell Pharmaceuticals Holdings (PARN) & Sophiris Bio (NASDAQ:SPHS)
www.americanbankingnews.com - July 8 at 2:18 PM
Sophiris Bio (SPHS) Doses First Patient in Phase 2b Study of Topsalysin to Treat Prostate Cancer - StreetInsider.comSophiris Bio (SPHS) Doses First Patient in Phase 2b Study of Topsalysin to Treat Prostate Cancer - StreetInsider.com
www.streetinsider.com - June 10 at 1:13 AM
Sophiris Bio Begins Dosing Patients in Phase 2b Study of Topsalysin to Treat Prostate CancerSophiris Bio Begins Dosing Patients in Phase 2b Study of Topsalysin to Treat Prostate Cancer
www.nasdaq.com - June 9 at 12:06 AM
Sophiris Bio (SPHS) Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate Cancer at AUASophiris Bio (SPHS) Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate Cancer at AUA
www.streetinsider.com - May 16 at 7:54 PM
BUZZ-U.S. STOCKS ON THE MOVE-Snap, Home Depot, Pfizer, Akebia - NasdaqBUZZ-U.S. STOCKS ON THE MOVE-Snap, Home Depot, Pfizer, Akebia - Nasdaq
www.nasdaq.com - May 16 at 9:05 AM
Sophiris Bio (SPHS) Presents Topsalysin Data from Phase 2a Proof ... - StreetInsider.comSophiris Bio (SPHS) Presents Topsalysin Data from Phase 2a Proof ... - StreetInsider.com
www.streetinsider.com - May 15 at 9:12 AM
Sophiris Bio (SPHS) Says Topsalysin Data from Phase 2a Localized Prostate Cancer Study to be Presented at EAU - StreetInsider.comSophiris Bio (SPHS) Says Topsalysin Data from Phase 2a Localized Prostate Cancer Study to be Presented at EAU - StreetInsider.com
www.streetinsider.com - March 25 at 8:02 AM
Sophiris Bio Reports Data from Successful Phase 2a Localized Prostate Cancer StudySophiris Bio Reports Data from Successful Phase 2a Localized Prostate Cancer Study
www.nasdaq.com - March 24 at 7:50 PM
Sophiris Bio (SPHS) Says Topsalysin Data from Phase 2a Localized Prostate Cancer Study to be Presented at EAUSophiris Bio (SPHS) Says Topsalysin Data from Phase 2a Localized Prostate Cancer Study to be Presented at EAU
www.streetinsider.com - March 24 at 7:50 PM
Sophiris Bio to Present at 29th Annual ROTH Conference - PR Newswire (press release)Sophiris Bio to Present at 29th Annual ROTH Conference - PR Newswire (press release)
www.prnewswire.com - March 8 at 8:14 AM

SEC Filings

Sophiris Bio (NASDAQ:SPHS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sophiris Bio (NASDAQ:SPHS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sophiris Bio (NASDAQ SPHS) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.